UNSPSC 51271702: Sodium oxybate

This classification denotes an anesthesia adjuvant with the molecular formula C4H7O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7G33012534, chemically known as gamma-hydroxybutyric acid, sodium salt but generally known as sodium oxybate, which bears US NIH Compound Identifier 10412. European Medicines Agency schedules Sodium oxybate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14731MIG.

World Health Organization schedules sodium oxybate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SODIUM OXYBATE remains the US FDA Preferred Term for this commodity. Sodium oxybate bears US NLM identifiers UMLS ID C0037537 and NCI Concept Code C61870. SMILES: C(CC(=O)[O-])CO.[Na+].

UNSPSC 51271702 Sodium oxybate is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments procure generic multi-source pharmaceuticals and over-the-counter products under this code through established wholesaler networks and cooperative agreements, requiring vendors to provide detailed product information, maintain FDA compliance, and offer competitive pricing structures across multiple net-price and discount-based formats.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of Purchase, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic and OTC pharmaceutical products serving participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of them with chargeback systems in place. Pricing is weighted at 75 percent of the evaluation score, with administrative compliance, EDI capability, and pricing flexibility accounting for the remaining 25 percent. Awarded vendors will have a two-year initial contract term effective July 1, 2026, with optional extensions at MMCAP's discretion; incumbent responders' amendments will extend through June 30, 2028. All products must meet cGMP and DSCSA requirements, possess FDA approval, and maintain a minimum six-month shelf life with at least one year remaining to expiration at manufacture.